Cost-effectiveness of apixaban vs. aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial
In patients with SCAF and a CHA2DS2-VASc score > 4, apixaban is cost saving in Canada and the UK and cost-effective in Germany. Apixaban was not cost-effective in the USA under the base cost assumption but would be cost-effective at a daily cost of $4.35 and cost saving at $3.59.
Authors
- Charlotte Larroudé
- Stefan H. Hohnloser (ORCID: https://orcid.org/0000-0001-5030-3315)
- Jeff S. Healey (ORCID: https://orcid.org/0000-0003-1216-7580)
- Michael R. Gold (ORCID: https://orcid.org/0000-0002-4579-0216)
- A. John Camm (ORCID: https://orcid.org/0000-0002-2536-2871)
- Christopher Bull Granger (ORCID: https://orcid.org/0000-0002-0045-3291)
- Wesley Tong (ORCID: https://orcid.org/0000-0003-2983-6103)
- David H. Birnie (ORCID: https://orcid.org/0000-0001-6495-1428)
- Juan Benezet‐Mazuecos (ORCID: https://orcid.org/0000-0003-3912-8901)
- Valentina Kutyifa (ORCID: https://orcid.org/0000-0002-0016-289X)
- Cecilia M. Linde (ORCID: https://orcid.org/0000-0002-9039-6023)
- Marco Alings (ORCID: https://orcid.org/0000-0003-2090-4683)
- William F. McIntyre (ORCID: https://orcid.org/0000-0001-6082-7542)
- Julia W. Erath (ORCID: https://orcid.org/0000-0003-3145-6767)
- David J. Wright (ORCID: https://orcid.org/0000-0002-5783-6648)
- Renato D. Lópes (ORCID: https://orcid.org/0000-0003-2999-4961)
- Roopinder K. Sandhu (ORCID: https://orcid.org/0000-0002-2629-3476)
- Josef Kautzner (ORCID: https://orcid.org/0000-0002-1632-6182)
- Christian Sticherling (ORCID: https://orcid.org/0000-0001-8428-7050)
- Dan Atar (ORCID: https://orcid.org/0000-0003-1513-8793)
- Andre L. Lamy (ORCID: https://orcid.org/0000-0003-2777-7621)
- Jan M. Nielsen (ORCID: https://orcid.org/0000-0003-0631-0010)
Institutions
- Semmelweis University (HU)
- Goethe University Frankfurt (DE)
- Oslo University Hospital (NO)
- Karolinska University Hospital (SE)
- Goethe-Institute United Kingdom (GB)
- University of Liverpool (GB)
- Medical University of South Carolina (US)
- University of Ottawa (CA)
- University of Alberta (CA)
- St George's, University of London (GB)
- University of Calgary (CA)
- Duke University (US)
- University of Oslo (NO)
- Aarhus University (DK)
- Hospital Universitario La Paz (ES)
- Aarhus University Hospital (DK)
- University Hospital of Basel (CH)
- Gentofte Hospital (DK)
- Population Health Research Institute (CA)
- Liverpool Heart and Chest Hospital (GB)
- Clinical Research Institute (US)
- Hospital La Luz (ES)
- Hospital Base (CL)
- Amphia Ziekenhuis (NL)
- Canadian VIGOUR Centre (CA)
- Institute of Clinical and Experimental Medicine (CZ)
- Department of Biomedicine Basel (CH)
- University Hospital Frankfurt (DE)
- Institute of Molecular and Clinical Ophthalmology Basel (CH)
- University of Rochester (US)
- McMaster University (CA)
Publication Details
- Journal
- EP Europace
- Published
- 2025-08-27
- DOI
- https://doi.org/10.1093/europace/euaf195
- Citations
- 2
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 6.26